Victoria Johnson

COPD management evolves with biologics, emphasizing personalized care and treatable traits to improve patient outcomes and address ongoing challenges.

COPD management evolves with targeted biologic therapies, enhancing treatment precision and improving patient outcomes in respiratory care.

Acute kidney injury mortality rises in wealthier nations, highlighting urgent need for targeted prevention strategies.

Sibeprenlimab shows promising results in reducing proteinuria and improving kidney health in IgA nephropathy.

A recent study reveals that younger patients with glomerular disease face a higher lifetime risk of kidney failure despite similar progression rates.

New research shows nearly all adults with hypertensive chronic kidney disease benefit from a <120 mm Hg target.

New data on daily fish oil supplementation prompts discussions on clinical recommendations.

Tegoprubart shows promise as a safer alternative to tacrolimus in kidney transplants, enhancing graft function with fewer side effects.

New findings reveal sparsentan significantly reduces proteinuria in FSGS patients, offering hope for improved kidney health and lower failure risk.

Experts discuss the latest advancements in pediatric atopic dermatitis treatment.

FDA launches the Commissioner’s National Priority Voucher program, expediting drug reviews for critical health needs.

An audio recap of the top 5 stories in healthcare news from the week of 10/12-18.

Experts discuss how innovative treatments are revolutionizing atopic dermatitis care for children.

Tezepelumab is the first TSLP-targeting biologic to be approved for chronic rhinosinusitis with nasal poylps.

Experts explore the evolution of asthma and COPD treatments with targeted biologic therapies.

The therapy is currently approved in almost 50 countries under the name Trimbow.

A recent study reveals that hypertonic saline and carbocisteine do not effectively reduce pulmonary exacerbations.

New long-term data reveals that Papzimeos offers sustained relief for adults with recurrent respiratory papillomatosis, reducing the need for surgeries.

An audio recap of the top 5 stories in healthcare news from the week of 10/5-10/11.

The therapy was well-tolerated in the phase 2a ENV-IPF-101 trial, with mostly mild-to-moderate TEAEs related to treatment.

The new therapy, marketed as Jascayd, previously demonstrated safety and efficacy in the phase 3 FIBRONEER-IPF trial.

INO-3107 immunotherapy significantly reduces surgeries for recurrent respiratory papillomatosis.

An audio recap of the top 5 stories in healthcare news from the week of 9/28-10/04.

Q3 2025 saw more research emerge in asthma therapeutics and management as well as rarer pulmonary diseases.

September 2025 saw 1 new approval, new long term data on smoking and emphysema, and more.

Less than optimal outcomes with ASCVD also increased healthcare resource utilization and costs.

New research supports fimasartan, atorvastatin, and ezetimibe combination to blood pressure and cholesterol levels.

Cytisinicline shows promise as a safe and effective smoking cessation treatment, significantly improving quit rates in COPD.

AstraZeneca's Airsupra gains FDA approval for mild asthma, expanding its current label.

The EXHALE-4 study evaluating the oral small molecule has met its primary endpoint of improving pre-BD FEV1.